The good news continues for Zoll Medical Corp. One day after posting solid Q2 2010 number, that Chelmsford company reported it has won approval to sell a new combined monitor and defibrillator unit.
The U.S. Food and Drug Administration awarded Zoll (Nasdaq: ZOLL) 510(k) clearance to start selling the new Propaq MD Monitor/Defibrillator, an ultra-light, compact device that was developed specifically to meet the special needs of military customers and air medical operations.
Zoll worked with the medical diagnostics firm Welch Allyn under a cooperative agreement, and was funded by grants from the U.S. Army Medical Research and Development Command, according to officials. One of the unit’s unique features is that its vital signs display can be turned to a night vision mode, so it can be seen by medical personnel using night vision equipment without giving away the position to an enemy.
On Thursday, Zoll reported that its third quarter experienced a bump in revenue, climbing to $111.3 million versus $95.1 million for the third quarter of 2009. Profit, however, spiked to $5.7 million for the quarter, against the $1.5 million in Q3 2009. At the time, the company noted that a drop in the military segment of its hospital business brought the overall North American hospital market down 8 percent from Q3 2009.
In December of 2009, Zoll won U.S. Food and Drug Administration 510(k) clearance for its Zoll E Series Monitor/Defibrillator with carbon monoxide monitoring.